Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Collegium Announces Authorized Generic Agreement with Hikma for Nucynta® and Nucynta® ER
Details : Through the agreement, Collegium will exclusively manufacture and supply Hikma with all authorized generic products for sale, including Nucynta-Generic (tapentadol HCl).
Product Name : Nucynta-Generic
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 29, 2024
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Collegium Pharmaceutical
Deal Size : $375.0 million
Deal Type : Agreement
Assertio Announces Sale of NUCYNTA® Franchise to Collegium
Details : Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : $375.0 million
June 02, 2020
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Collegium Pharmaceutical
Deal Size : $375.0 million
Deal Type : Agreement
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2019
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 20, 2019
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2019
Lead Product(s) : Tapentadol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Depomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Palexia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2014
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Depomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 30, 2014
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Depomed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 07, 2014
Lead Product(s) : Tapentadol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Depomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 24, 2013
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 11, 2013
Lead Product(s) : Tapentadol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
